Literature DB >> 2039322

Evaluation of neck lymph node dissection for thoracic esophageal carcinoma.

H Kato1, H Watanabe, Y Tachimori, T Iizuka.   

Abstract

We studied a series of 150 patients treated for thoracic esophageal carcinoma at our institution. The patients were divided into two matched groups. Group B underwent transthoracic esophagectomy with mediastinal and abdominal lymphadenectomy only; group A also underwent bilateral neck lymph node dissection. The rates of operative mortality and operative complications did not differ significantly between the two groups. The 5-year survival rate was 38.7% overall (48.7% in group A and 33.7% in group B). Group A had a significantly better survival curve than group B. Twenty patients (26.0%) in group A had metastasis in the dissected neck lymph nodes. The 4-year survival rate of these patients was 47.9%. The significantly better survival of group A and the satisfactory prognosis in the patients with positive cervical lymph nodes demonstrates the effectiveness of neck lymph node dissection in radical operation for thoracic esophageal carcinoma.

Entities:  

Mesh:

Year:  1991        PMID: 2039322     DOI: 10.1016/0003-4975(91)91008-j

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  55 in total

1.  Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years.

Authors:  N Ando; S Ozawa; Y Kitagawa; Y Shinozawa; M Kitajima
Journal:  Ann Surg       Date:  2000-08       Impact factor: 12.969

Review 2.  Cervical lymph node metastases from remote primary tumor sites.

Authors:  Fernando López; Juan P Rodrigo; Carl E Silver; Missak Haigentz; Justin A Bishop; Primož Strojan; Dana M Hartl; Patrick J Bradley; William M Mendenhall; Carlos Suárez; Robert P Takes; Marc Hamoir; K Thomas Robbins; Ashok R Shaha; Jochen A Werner; Alessandra Rinaldo; Alfio Ferlito
Journal:  Head Neck       Date:  2015-12-29       Impact factor: 3.147

3.  [Preoperative evaluation of prognostic factors in esophageal squamous cell cancer].

Authors:  P M Schneider; D Vallböhmer; J Brabender; A H Hölscher
Journal:  Chirurg       Date:  2005-11       Impact factor: 0.955

Review 4.  Current management of esophageal cancer.

Authors:  Simon Law; John Wong
Journal:  J Gastrointest Surg       Date:  2005-02       Impact factor: 3.452

Review 5.  Multimodal treatment for resectable esophageal cancer.

Authors:  Hiroshi Miyata; Makoto Yamasaki; Yukinori Kurokawa; Shuji Takiguchi; Kiyokazu Nakajima; Yoshiyuki Fujiwara; Masaki Mori; Yuichiro Doki
Journal:  Gen Thorac Cardiovasc Surg       Date:  2011-07-14

6.  Esophagectomy with three-field lymph node dissection for esophageal carcinoma with a nonrecurrent inferior laryngeal nerve.

Authors:  Hiroshi Sato; Yasuhiro Tsubosa; Toru Ugumori
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2005-09

7.  The impact of cervical lymph node dissection on acid and duodenogastroesophageal reflux after intrathoracic esophagogastrostomy following transthoracic esophagectomy.

Authors:  Soichiro Asai; Masahide Fukaya; Kazushi Miyata; Keita Itatsu; Ryoji Miyahara; Kazuhiro Furukawa; Tomoki Ebata; Masato Nagino
Journal:  Surg Today       Date:  2019-06-19       Impact factor: 2.549

8.  Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival, and outcome: a plea for adaptation of TNM classification in upper-half esophageal carcinoma.

Authors:  T Lerut; P Nafteux; J Moons; W Coosemans; G Decker; P De Leyn; D Van Raemdonck; N Ectors
Journal:  Ann Surg       Date:  2004-12       Impact factor: 12.969

9.  Tumor spread in superficial esophageal cancer: histopathologic basis for rational surgical treatment.

Authors:  T Nishimaki; O Tanaka; T Suzuki; K Aizawa; H Watanabe; T Muto
Journal:  World J Surg       Date:  1993 Nov-Dec       Impact factor: 3.352

10.  Inverse correlation of HER2 with MHC class I expression on oesophageal squamous cell carcinoma.

Authors:  T Maruyama; K Mimura; E Sato; M Watanabe; Y Mizukami; Y Kawaguchi; T Ando; H Kinouchi; H Fujii; K Kono
Journal:  Br J Cancer       Date:  2010-07-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.